NCT03333057View on ClinicalTrials.gov

Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

PHASE2CompletedINTERVENTIONAL
Enrollment

336

Participants

Timeline

Start Date

January 3, 2018

Primary Completion Date

May 18, 2018

Study Completion Date

July 27, 2018

Conditions
Dry Eye Disease (DED)
Interventions
DRUG

NOV03

Perfluorohexyloctane

DRUG

Placebo

Saline solution (0.9% sodium chloride solution)

Trial Locations (11)

32256

Investigational site, Jacksonville

37205

Investigational Site, Nashville

37215

Investigational Site, Nashville

60046

Investigational Site, Lake Villa

64111

Investigational Site, Kansas City

90505

Investigational Site, Torrance

90701

Investigational site, Artesia

92660

Investigational Site, Newport Beach

92663

Investigational Site, Newport Beach

92705

Investigational Site, Santa Ana

08534

Investigational Site, Pennington

Sponsors

Lead Sponsor

Novaliq GmbH
All Listed Sponsors
lead

Novaliq GmbH

INDUSTRY